Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of ABT-751 in Patients With Colorectal Cancer

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00073138
First received: November 17, 2003
Last updated: November 28, 2007
Last verified: November 2007
  Purpose

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.


Condition Intervention Phase
Colorectal Cancer
Drug: ABT-751
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma

Resource links provided by NLM:


Further study details as provided by Abbott:

Primary Outcome Measures:
  • Objective Response Rate in subjects with Recurrent Colorectal Cancer [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Time to Tumor Progression (TTP) [ Time Frame: 1 year ]
  • Survival [ Time Frame: 2 years ]
  • Toxicities associated with treatment administration [ Time Frame: 1 year ]

Estimated Enrollment: 40
Study Start Date: August 2003
Study Completion Date: February 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Colorectal cancer.
  • Recurrent tumor following treatment with irinotecan and/or oxaliplatin.
  • Able to tolerate normal activities of daily living.
  • Adequate bone marrow, kidney, and liver function.

Exclusion Criteria

  • Pregnant or breast feeding.
  • Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
  • Prior radiation therapy.
  • CNS metastasis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00073138

Locations
United States, California
University of Southern California
Los Angeles, California, United States, 90089
Cancer Institute Medical Group
Santa Monica, California, United States, 90095-3961
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611-5933
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Wisconsin
University of Wisconsin Medical Center
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Abbott
Investigators
Study Director: Helen Eliopoulos, MD Abbott
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00073138     History of Changes
Other Study ID Numbers: M02-446
Study First Received: November 17, 2003
Last Updated: November 28, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases

ClinicalTrials.gov processed this record on November 20, 2014